Mayendraraj A, Rosenkilde MM, Gasbjerg LS
Rates were higher than previously reported for GLP-1 mono agonists (semaglutide) and dual agonists (tirzepatide), which is consistent with a stronger overall incretin load
The rate of weight loss accelerates as doses escalate during the titration phase, with most clinical trial participants losing 5% to 10% of baseline body weight by week 12
What to do about new costs Depending on how the new research turns out, adding some of the indications discussed here could add many millions of potential patients who might benefit from GLP-1 medicines
Use Follow Trainer so your speed, incline, decline, and resistance automatically follow your on-screen iFIT Trainer when you train on compatible iFIT equipment
The group was reviewing a paper on tirzepatide, a GLP-1 agonist, which reported that the drugs efficacy for weight loss was nearly comparable to that of bariatric surgery